Back to top
more

Celgene Corporation (CELG)

(Delayed Data from NSDQ)

$96.88 USD

96.88
5,654,306

+1.67 (1.75%)

Updated May 3, 2019 04:00 PM ET

After-Market: $96.84 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks News

Company News For Jan 18, 2018

Companies In The News are: TIF,CSX,JUNO,CELG,FAST

    J&J (JNJ) Hits New 52-Week High: What's Driving the Stock?

    Promising data from several pivotal studies and a rapid pipeline progress contribute to a rally in Johnson & Johnson's (JNJ) shares.

      Novartis sBLA for CAR-T Therapy Kymriah Accepted by FDA

      Novartis (NVS) gets a significant boost with the FDA approval of CAR-T Therapy Kymriah and the company is now looking to expand the therapy's label.

        Arpita Dutt headshot

        3 Top-Ranked Drug Stocks that are Broker Favorites

        With the pharma and biotech sector performing well in 2017, here is a look at three drug stocks including Vertex (VRTX) that are broker favorites.

          Is Celgene (CELG) Looking to Take Over Juno Therapeutics?

          There are reports that Celgene (CELG) is in talks to acquire Juno Therapeutics to strengthen its portfolio given the recent series of setbacks.

            Arpita Dutt headshot

            Biotech Stock Roundup: Juno Surges on Acquisition Rumor, Concert Down on Patent News

            Is Celgene (CELG) in talks with Juno regarding a possible acquisition deal? This was the main news in the biotech sector this week.

              Concert Pharmaceuticals Plunges on Patent Petition Setback

              Shares of Concert Pharmaceuticals (CNCE) nosedive after the Patent Trial and Appeal Board decided not to grant a Post Grant Review petition in patent '335 dispute with Incyte.

                The Zacks Analyst Blog Highlights: Celgene, Amgen, Exelixis, Alexion and Vertex

                The Zacks Analyst Blog Highlights: Celgene, Amgen, Exelixis, Alexion and Vertex

                  Arpita Dutt headshot

                  Key Takeaways from Pfizer & 3 Other Drug Stocks at Healthcare Conference

                  Here is a look at key takeaways from presentations made by four major pharma and biotech stocks including Pfizer (PFE) at the annual J.P. Morgan healthcare conference.

                    Celgene Provides 2017 Preliminary Results & 2018 View

                    Celgene Corporation (CELG) provided preliminary results for 2017 and upbeat guidance for 2018. The company suffered a few setbacks of late and is looking to bolster its pipeline.

                      Celgene to Acquire Impact Biomedicines to Boost Pipeline

                      Celgene (CELG) announced that it will acquire Impact Biomedicines to bolster its oncology pipeline given the recent series of setbacks.

                        Will J&J (JNJ) Continue to Tread Growth Path This Year?

                        Johnson & Johnson's (JNJ) stock was up last year. The positive trend is likely to continue this year as well.

                          What Drives Juno Therapeutics (JUNO) Above 150% This Year

                          We take a look at the factors especially the focus on CAR-T therapy that led to the phenomenal growth in Juno Therapeutics (JUNO) share price in 2017.

                            Celgene (CELG) in Troubled Waters in '17: What Does 2018 Hold?

                            Celgene's (CELG) stock has been under pressure due to pipeline setbacks. We expect an acquisition in the offing to bolster its portfolio.

                              Company News For Dec 28, 2017

                              Companies In The News are: TSLA,BA,CELG,WATT

                                4 Biotech Stocks Ready to Crush the Market in 2018

                                The biotech sector has performed well in 2017 and we expect the momentum to continue in 2018 driven by new drug approvals. Here, we list stocks which might be worth adding to your biotech portfolio for 2018.

                                  Agios (AGIO) Files NDA for Leukemia Candidate in the U.S.

                                  Agios (AGIO) submits new drug application to the FDA for ivosidenib for relapsed or refractory acute myeloid leukemia and IDH1 mutation. The company has also filed request for a priority review.

                                    Why is Corcept's Stock Up More Than 150% So Far This Year?

                                    We take a look at the factors that drove the phenomenal growth in share price of Corcept (CORT) in 2017.

                                      Arpita Dutt headshot

                                      Biotech Stock Roundup: BIIB, CELG Hit by Pipeline News, Acquisition Deals for Ignyta, Sucampo

                                      A couple of acquisition agreements as well as pipeline news from Celgene (CELG) and Biogen were the key highlights this week in the biotech sector.

                                        Celgene (CELG) Down on Discouraging Data on Revlimid

                                        Celgene (CELG)'s stock declined as the phase III study, REVELANCE, for the label expansion of key drug Revlimid for untreated follicular lymphoma patients failed.

                                          4 Biotech Stocks That More Than Doubled This Year

                                          We take a look at a few biotech stocks whose price has increased more than 100% in 2017.

                                            Arpita Dutt headshot

                                            Biotech Stock Roundup: ASH Data in Focus, Gilead to Buy Cell Design Labs

                                            The annual meeting of the American Society of Hematology was the key highlight this week with several companies like bluebird (BLUE) presenting data on their investigational treatments.

                                              Juno Reports Additional Data on CAR-T Therapy, Shares Drop

                                              Juno (JUNO) releases additional results from the ongoing phase I study of its chimeric antigen receptor T-cell (CAR-T) therapy candidate, JCAR017.

                                                Bluebird's Shares Jump on Strong Data for CAR-T Therapy

                                                bluebird (BIRD) announced updated results from the ongoing phase I study of its chimeric antigen receptor T-cell (CAR-T) therapy candidate- bb2121.

                                                  Gilead (GILD) Posts Updated Data on CAR-T Therapy Yescarta

                                                  Gilead (GILD) announced follow-up data from a phase II study, on its CAR-T therapy, Yescarta for treatment of refractory large B-cell lymphoma.